Medical Science Liaison - South West
Medical Affairs | Field Based | Full Time
Oncopeptides is a global biotech company committed to developing targeted therapies for patients facing hard-to-treat hematological diseases. Oncopeptides has one U.S. FDA approved product, PEPAXTO® (melphalan flufenamide), known during clinical development as melflufen. PEPAXTO is approved for patients with triple-class refractory multiple myeloma and was evaluated in several clinical studies including the pivotal Phase 2 HORIZON study and is currently being evaluated in the confirmatory Phase 3 OCEAN study. Oncopeptides’ headquarters is in Stockholm, Sweden, with a U.S. headquarters in Boston, Massachusetts. In addition to Boston, Oncopeptides has a footprint in Los Altos, California, another U.S. biotech hub. PEPAXTO® is a trademark of Oncopeptides AB (publ).
The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
The company is in a strong financial position and has an effective Executive Team and Board of Directors. Discover more about Oncopeptides at www.oncopeptides.com
The MSL, who is field based, is responsible for developing, coordinating and assuring implementation of Oncopeptides corporate, scientific, and clinical strategies in her/his loco-regional area/territory.
The MSL will function as a subject matter expert and engage thought leaders, payers and other stakeholders specializing in the delivery of hematology and oncology therapeutics and supportive care in medical and scientific exchanges. These exchanges will be performed in a compliant fashion. Insights gathered and the information shared during these exchanges will be used to support and/or expand current clinical and scientific concepts including and related to disease state and therapeutic awareness. Furthermore, these exchanges will inform development and business strategies. They will also ensure the safe and effective utilization of Oncopeptides product(s). The MSL is responsible for cultivating and maintaining collaborative relationships with influential members of her/his loco-regional medical community to enable the conduct of these scientific exchanges.
Support of Oncopeptides research initiatives is another important role of the MSL. MSLs will work with other members of the organization, corporate partners, and investigators to compliantly support corporate sponsored clinical trials, Real World Data generation, and investigator-sponsored studies. MSLs will also participate in and contribute to projects and initiatives that increase the value and productivity of the Medical Affairs team.
This position is field-based for our South West Region - Arizona, California and Nevada.
Domestic and international travel up to 50%.
Key responsibilities include, but are not limited to:
Establish Oncopeptides as a leading company committed to patient access and the advancement of Pepaxto and other novel peptide-drug conjugates as a treatment option for hematologic cancers.
Maintain clinical, scientific and technical expertise in multiple myeloma (and other relevant disease state areas).
Have a thorough understanding of the development process for Pepaxto and other Oncopeptides products, clinical protocols and related procedures.
Collaborate with other members of the medical affairs, clinical development, commercial teams; serve as an Oncopeptides resource to HCPs, large group medical practices, payers and formulary decision makers.
Develop and track key opinion leader (KOL) engagement plans – identify, develop and maintain long-term collaborative relationships with KOLs within assigned region.
Participate in medical and scientific exchanges with the medical/ scientific community including advisory boards in a compliant manner
Provide medical/ clinical teams with feedback and insights from interactions with KOLs and investigators
Respond to and document unsolicited requests for information on Oncopeptides’ products and clinical programs.
Support internal requests for dossier review and comment, medical review/consideration of potential business development opportunities and other unique projects as requested.
Participate in/support the training of Oncopeptides field and home office employees.
Facilitate research collaborations (including REMS programs, Real World Data [RWD] generation and investigator initiated trials [IITs) with key investigators including helping identify, establish and maintain such collaborations.
Represent the company at medical meetings through Medical Affairs’ Scientific Booth coverage and other related activities.
Engage in speaker identification, training and evaluation and provide support for advisory board meetings as requested.
Collaborate with Market Access and Commercial colleagues for thought leader and institutional engagement where appropriate.
Adhere to corporate SOPs and ensure vigilant compliance with relevant legal and regulatory guidelines governing scientific interactions with physicians and healthcare professionals across all activities, including those related to clinical trials, scientific interactions with internal and external groups, and responses to unsolicited requests for medical/ scientific information.
An advanced degree required (Pharm D, PhD or MD) preferred; advanced professional degree (e.g. NP, PA, R.Ph., MA, BSN) will be considered
A minimum of 2 years previous MSL experience in hematology/oncology, preferable focus on Multiple Myeloma (will consider other pharmaceutical industry experience, e.g. Medical Information, Medical Communications or Research, etc.)
Ability to travel, locally and regionally, up to 50% with overnight stays (e.g., KOL meetings, site locations, internal meetings, medical meetings and congresses, training)
Experience working with payers of formulary committees strongly preferred
Knowledge of FDA requirements and PhRMA Code, including regulations governing compliant scientific exchange
Demonstrated ability to integrate and work in cross functional network/matrix
Demonstrated project management ability
Excellent communication (oral and written) and interpersonal skills
Valid driver’s license
Driven by the Oncopeptides Values
- Science driven
- Patient focused